Background: The triglyceride (TG) content of low-density lipoprotein (LDL-TG) has been shown to be more predictive of atherosclerotic cardiovascular disease (ASCVD) events than the cholesterol content of LDL (LDL-C). The goal of our study was to develop an equation for estimating LDL-TG (LDL-TG) based on the standard lipid panel and to compare it to estimated LDL-C as an ASCVD risk biomarker.
Methods: Using least-square regression analysis, the following LDL-TG equation was developed: . LDL-TG was measured by the -quantification (BQ) reference method ( = 40,202). LDL-C was calculated by the Sampson-NIH equation. The association of LDL-C and LDL-TG with ASCVD risk markers was performed in the National Heart and Nutrition Examination Survey (NHANES) ( = 37,053) and with ASCVD events in a primary prevention cohort from the UK Biobank (UKB) ( = 429,367) and the Atherosclerosis Risk in Communities (ARIC) study ( = 14,632).
Results: LDL-TG showed better ASCVD risk stratification of UKB participants than LDL-C (Wilcoxon Chi-Square: 2,099.6 vs. 418.7, respectively). Receiving-operating characteristics analysis revealed that LDL-TG had a stronger association with ASCVD events than LDL-C (AUC: 0.596 vs. 0.542, respectively) and other conventional lipid markers. Similar findings were found in ARIC. Discordance analysis in UKB showed that the group with low LDL-C/high LDL-TG had a similar risk as the high LDL-C/high LDL-TG group. Furthermore, these same two groups with the highest LDL-TG levels and the highest ASCVD event rate also had higher mean levels of systolic blood pressure, Body Mass Index, hemoglobin A1C, and C-reactive protein than the two lower LDL-TG groups. Using LDL-TG > 44.6 mg/dl (80th percentile) as a cut-point leads to a hazard ratio of 1.32 (95% CI, 1.29-1.36) for ASCVD events, which remained significant after adjustment for LDL-C and apoB. Furthemore, using LDL-TG as a risk-enhancer test leads to reclassification of 50% more high-risk individuals than current lipid-enhancer test rules.
Conclusions: Like LDL-C, LDL-TG can also be calculated from the results of the standard lipid panel. Compared to estimated LDL-C, LDL-TG was a better risk marker for primary prevention and hence could improve initial ASCVD risk stratification.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543484 | PMC |
http://dx.doi.org/10.3389/fcvm.2024.1452869 | DOI Listing |
JACC Adv
January 2025
Department of Epidemiology, University of California, Los Angeles, California, USA.
Background: There is significant heterogeneity in cardiovascular disease (CVD) risk among patients with diabetes mellitus (DM).
Objectives: The purpose of this study was to develop risk scores for total CVD and its components from a contemporary pooled, observational cohort of U.S.
BMC Med
January 2025
Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Peking Union Medical College and Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, No. 1 Shuaifuyuan, Wangfujing Ave, Beijing, 100730, China.
Background: Patients with systemic lupus erythematosus (SLE) suffered from an increasing risk of cardiovascular diseases. In this multi-center prospective study, we aimed to determine the association between antiphospholipid antibodies (aPLs) and future atherosclerotic cardiovascular disease (ASCVD) in SLE.
Methods: In total, 1573 SLE patients were recruited based on the Chinese SLE Treatment and Research group (CSTAR) registry.
J Atheroscler Thromb
December 2024
Victorian Heart Institute, Monash University.
Atherosclerotic cardiovascular disease (ASCVD) is a leading global cause of mortality, and recent research has underscored the critical role of lipoproteins in modulating cardiovascular (CV) risk. Elevated low-density lipoprotein cholesterol (LDL-C) levels have been linked to increased CV events, and while numerous trials have confirmed the efficacy of lipid-lowering therapies (LLT), significant gaps remain between recommended LDL-C targets and real-world clinical practice. This review addresses care gaps in LLT, emphasizing the necessity for innovative approaches that extend beyond LDL-C management.
View Article and Find Full Text PDFAm J Cardiol
January 2025
Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL 35233; Section of Cardiology, Birmingham Veterans Affairs Medical Center, Birmingham, AL 35233. Electronic address:
The Pooled-Cohort Equations (PCEs), developed by the American Heart Association (AHA) and American College of Cardiology (ACC), have been widely used since 2013 to estimate 10-year atherosclerotic cardiovascular disease (ASCVD) risk and guide statin therapy. Recently, the AHA introduced the Predicting Risk of CVD EVENTs (PREVENT) equations to improve ASCVD risk estimation. However, the effect of using PREVENT instead of PCEs on risk classification and statin eligibility remains unclear.
View Article and Find Full Text PDFSci Rep
January 2025
Student Research Committee, Fasa University of Medical Sciences, Fasa, Iran.
The first step to reducing the growing burden of cardiovascular disease (CVD) is to find modifiable risk factors with the highest burden in each population. Urban and rural citizens may have different priorities in this regard. This study aimed to compare the 10-year incidence probability of CVD events and its associated risk factors between rural and urban areas in Iran.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!